MA28213A1 - Derives de bengamide, procede de production de ceux-ci et leur utilisation pour le traitement du cancer - Google Patents

Derives de bengamide, procede de production de ceux-ci et leur utilisation pour le traitement du cancer

Info

Publication number
MA28213A1
MA28213A1 MA28955A MA28955A MA28213A1 MA 28213 A1 MA28213 A1 MA 28213A1 MA 28955 A MA28955 A MA 28955A MA 28955 A MA28955 A MA 28955A MA 28213 A1 MA28213 A1 MA 28213A1
Authority
MA
Morocco
Prior art keywords
cancer
producing
treatment
same
bengamide derivatives
Prior art date
Application number
MA28955A
Other languages
English (en)
Inventor
Holger Hoffmann
Sabine Haag-Richter
Michael Kurz
Heiko Tietgen
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of MA28213A1 publication Critical patent/MA28213A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/08—Oxygen atoms
    • C07D223/10—Oxygen atoms attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/12—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/10—Nitrogen as only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne des dérivés de bengamide qui sont formés par le micro-organisme Myxococcus virescens ST200611 (DSM 15898), pendant la fermentation, leur utilisation pour traiter des maladies cancéreuses, des médicaments contenant lesdits dérivés de bengamide, un procédé de préparation de bengamides de formule (V), ainsi que le micro-organisme Myxococcus virescens ST200611 (DSM 15898).
MA28955A 2003-10-24 2006-04-21 Derives de bengamide, procede de production de ceux-ci et leur utilisation pour le traitement du cancer MA28213A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10349669A DE10349669B3 (de) 2003-10-24 2003-10-24 Bengamide-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung

Publications (1)

Publication Number Publication Date
MA28213A1 true MA28213A1 (fr) 2006-10-02

Family

ID=34484998

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28955A MA28213A1 (fr) 2003-10-24 2006-04-21 Derives de bengamide, procede de production de ceux-ci et leur utilisation pour le traitement du cancer

Country Status (30)

Country Link
EP (2) EP1680405B1 (fr)
JP (1) JP4769190B2 (fr)
KR (1) KR20060120044A (fr)
CN (2) CN101294173A (fr)
AR (1) AR046553A1 (fr)
AT (2) ATE477244T1 (fr)
AU (1) AU2004287561B2 (fr)
BR (1) BRPI0415529A (fr)
CA (1) CA2543003A1 (fr)
CL (1) CL2009000674A1 (fr)
CY (1) CY1110458T1 (fr)
DE (3) DE10349669B3 (fr)
DK (1) DK1680405T3 (fr)
ES (1) ES2320894T3 (fr)
HK (1) HK1098131A1 (fr)
HR (1) HRP20090187T1 (fr)
IL (1) IL174524A (fr)
MA (1) MA28213A1 (fr)
ME (1) MEP33108A (fr)
MX (1) MXPA06004084A (fr)
NO (1) NO20062149L (fr)
NZ (1) NZ546744A (fr)
PL (1) PL1680405T3 (fr)
PT (1) PT1680405E (fr)
RS (1) RS20060263A (fr)
RU (1) RU2357956C2 (fr)
SI (1) SI1680405T1 (fr)
UY (1) UY28574A1 (fr)
WO (1) WO2005044803A1 (fr)
ZA (1) ZA200602231B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2878525B1 (fr) * 2004-11-29 2007-02-23 Aventis Pharma Sa Bengamides possedant un cycle caprolactame substitue, procede de preparation, compositions les contenant et utilisation
FR2878528B1 (fr) 2004-11-29 2008-05-16 Aventis Pharma Sa 2-alcoxy-3,4,5-trihydroxy-alkylamides, leur preparation, compositions les contenant et utilisation
FR2901554B1 (fr) 2006-05-24 2011-04-01 Sanofi Aventis 2-alcoxy-3,4,5-trihydroxy-alkylamide-benzazepine, leur preparation, compositions les contenant et utilisation
FR2901556A1 (fr) 2006-05-24 2007-11-30 Sanofi Aventis Sa Derives de 2-alcoxy-3,4,5-trihydroxy-alkylamide, leur preparation, compositions les contenant et utilisation
FR2901555A1 (fr) 2006-05-24 2007-11-30 Sanofi Aventis Sa 2-alcoxy-3,4,5-trihydroxy-alkylamide-benzothiazepine, leur preparation, compositions les contenant et utilisation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5140099A1 (es) * 1998-11-17 2002-03-22 Novartis Ag Ciertas caprolactamas sustituidas, composiciones farmaceuticas que las contienen, y su uso en el tratamiento de tumores
EP1282604B1 (fr) * 2000-05-11 2008-01-09 Novartis AG Carbonates et ethers de caprolactame substitues et utilisation de ceux-ci comme agents anti tumoraux
JP2004262793A (ja) * 2003-02-28 2004-09-24 Noyaku Bio Technology Kaihatsu Gijutsu Kenkyu Kumiai 化合物ｎ−９０１１、その製造法及び用途
MXPA06000975A (es) * 2003-07-25 2006-04-11 Novartis Ag Lactams sustituidos y su uso como agentes anti-cancer.

Also Published As

Publication number Publication date
DE10349669B3 (de) 2005-05-25
EP1873146A2 (fr) 2008-01-02
PL1680405T3 (pl) 2009-06-30
ATE420074T1 (de) 2009-01-15
RU2006117769A (ru) 2007-11-27
SI1680405T1 (sl) 2009-06-30
IL174524A0 (en) 2006-08-01
HK1098131A1 (en) 2007-07-13
CY1110458T1 (el) 2015-04-29
ZA200602231B (en) 2007-06-27
EP1680405B1 (fr) 2009-01-07
NO20062149L (no) 2006-07-11
JP2007509084A (ja) 2007-04-12
ES2320894T3 (es) 2009-05-29
IL174524A (en) 2012-08-30
WO2005044803A1 (fr) 2005-05-19
HRP20090187T1 (en) 2009-05-31
NZ546744A (en) 2009-03-31
MXPA06004084A (es) 2006-06-27
DE502004011536D1 (de) 2010-09-23
KR20060120044A (ko) 2006-11-24
CN1871217A (zh) 2006-11-29
AU2004287561B2 (en) 2011-06-02
JP4769190B2 (ja) 2011-09-07
AU2004287561A1 (en) 2005-05-19
CL2009000674A1 (es) 2009-08-07
UY28574A1 (es) 2005-05-31
DE502004008837D1 (de) 2009-02-26
AR046553A1 (es) 2005-12-14
CN100398520C (zh) 2008-07-02
BRPI0415529A (pt) 2006-12-26
DK1680405T3 (da) 2009-05-04
CN101294173A (zh) 2008-10-29
MEP33108A (en) 2010-10-10
EP1873146A3 (fr) 2008-05-21
CA2543003A1 (fr) 2005-05-19
EP1873146B1 (fr) 2010-08-11
RS20060263A (en) 2008-09-29
PT1680405E (pt) 2009-03-31
RU2357956C2 (ru) 2009-06-10
ATE477244T1 (de) 2010-08-15
EP1680405A1 (fr) 2006-07-19

Similar Documents

Publication Publication Date Title
MA27769A1 (fr) Dérivées de 2-acylamino-4-phenylthiazole, leur préparation et leur application en thérapeutique
MA26718A1 (fr) Derives de quinoleine-2-one a substituant heteroaryle nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN05238A1 (fr) Derives du benzenesulfonamide, leur procede de preparation et leur utilisation pour le traitement de la douleur
MA27697A1 (fr) Derive de phenethanolamine utilise dans le traitement des maladies respiratoires
MA27608A1 (fr) Derives d'hydroxyethylamine utilises pour le traitement de la maladie d'alzheimer
MA27675A1 (fr) Derives de piperazine et leur utilisation dans le traitement de maladies neurologiques et psychiatriques
AU5584901A (en) Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease
TNSN07022A1 (fr) Derives de pyridine
UA48939C2 (uk) Дизаміщені фуранони, способи їх одержання, фармацевтична композиція на їх основі, спосіб лікування запального захворювання, проміжні сполуки
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
MA27668A1 (fr) 2,4-di(phenylamino) pyrimidines utilisees pour traiter des maladies neoplasiques, des troubles inflammatoires et des troubles du systeme immunitaire
MA27781A1 (fr) 3-fluoro-piperidines comme antagonistes de nmda/nr2b.
GEP20053660B (en) Novel Tyrosine Kinase Inhibitors
MY139552A (en) Phenethanolamine derivatives for treatment of respiratory diseases
MXPA04002405A (es) Derivados de fenetanolamina para tratamiento de enfermedades respiratorias.
MA29926B1 (fr) Derives de pyrazine
MXPA04005156A (es) Antagonistas del receptor de adenosina a2a.
SG151336A1 (en) 1,3,4-oxadiazol-2-ones as ppar delta
GB0313612D0 (en) Organic compounds
MA28213A1 (fr) Derives de bengamide, procede de production de ceux-ci et leur utilisation pour le traitement du cancer
YU47902A (sh) Novi polimorfi sertralin hidrohlorida, postupci za njihovo dobijanje, preparati koji ih sadrže i postupci za njihovu upotrebu
IL178167A0 (en) 1,3,4-oxadiazol-2-ones as ppar delta modulators
MA27676A1 (fr) 2-amino-6-(2-substitue-4-phenoxy)-substitue-pyridines, procede pour leur preparation et compositions pharmaceutiques les contenant
SE0104331D0 (sv) Novel compounds
MY128241A (en) Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors